Tag
Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamic
A novel B-cell acute lymphoblastic leukemia subtype characterized by IGH::FENDRR rearrangement and KRAS mutations shows distinct molecular features and poor response to standard chemotherapy, highlighting the need for early immunotherapy an
A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
Researchers found that IL-1β signaling drives growth, relapse, and bone damage in TCF3::HLF-positive B-ALL, suggesting IL-1β blockade may offer a new treatment strategy.
A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activ
Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.
